Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy

Overview of attention for article published in Investigational New Drugs, January 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (53rd percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

patent: 1 patent

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 42 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

MEDICAL APPLICATION OF RESMINOSTAT IN ASIAN PATIENTS

Application WO-2017178577-A1

World Intellectual Property Organisation (WIPO)